GPGiuseppe Di Pietro

Giuseppe Di Pietro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giuseppe Di Pietro has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Reasoning: A Patient With Progressive Sensory Neuropathy

    by Giuseppe Di Pietro, Pietro Falco, Eleonora Galosi, Enrico Evangelisti, Daniel Litewczuk, Gianfranco De Stefano, Giulia Di Stefano, Filippo Camerota, Caterina Leone, Andrea Truini

    A 74-year-old man presented with a 5-year history of progressive feet numbness followed by gait unsteadiness. Neurologic examination revealed absent tendon reflexes, markedly reduced vibration sens...

  • Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes

    by Pietro Falco, Alessandra Di Flaviani, Eleonora Galosi, Stefania Angotti, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Luca D'ONofrio, Enrico Evangelisti, Caterina Leone, et al.

    In this cross-sectional study, we investigated the frequency of diabetic peripheral neuropathy (DPN) and DPN-related neuropathic pain (painful DPN) in 500 consecutively enrolled patients with type 2 diabetes mellitus receiving standard treatment (n = 208), sodium–glucose cotransporter-2 inhibitors (SGLT2i; n = 152), or glucagon-like peptide-1 receptor agonists (GLP-1 RAs; n = 140). DPN was assessed through neurological examination, nerve conduction study, and skin biopsy when indicated; painful DPN was diagnosed using the grading system for neuropathic pain. Neuropathy severity and pain intensity were quantified with the Toronto Clinical Neuropathy Score, Pain Numerical Rating Scale, and Neuropathic Pain Symptom Inventory. The overall frequency of DPN was 58.6%, and painful DPN occurred in 26.2% of patients. GLP-1 RA treatment was associated with a lower frequency of DPN (46.4% vs 60.6% in the standard treatment group) and painful DPN (10.1% vs 35.1% and 28.3% in the standard treatment and SGLT2i groups, respectively). After adjustment for clinical and metabolic covariates, GLP-1 RA treatment was independently associated with lower odds of DPN (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.37-0.96) and painful DPN (OR 0.32, 95% CI 0.15-0.65). Neuropathy severity and pain intensity were also lower in patients receiving GLP-1 RAs. GLP-1 RA treatment was associated with a reduced frequency and severity of both DPN and painful DPN, independent of clinical and metabolic covariates. While these findings suggest potential neuroprotective and antinociceptive effects, longitudinal studies are needed to establish causality and clarify the underlying mechanisms.


  • Open Access

    Trigeminal root dislocation subtends focal demyelination of primary trigeminal afferents in patients with trigeminal neuralgia

    by G De Stefano, D Litewczuk, C. Mollica, C. Leone, E. Galosi, G Di Pietro, P. Falco, N. Esposito, E. Evangelisti, D. Chiffi, et al.


  • Open Access

    Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings

    by Giuseppe Di Pietro, Pietro Falco, Rocco Costanzo, Eleonora Galosi, Gianfranco De Stefano, Enrico Evangelisti, Antonio Lauletta, Caterina Leone, Daniel Litewczuk, Giulia Di Stefano, et al.

    Introduction/Aims: Inclusion body myositis (IBM) is an inflammatory myopathy with an insidious onset, often making diagnosis challenging. Although neuroimaging has recently been included in diagnostic criteria, the role of muscle ultrasound—despite being a rapid and cost‐effective tool—in IBM has been less extensively characterized. In this study, we aimed to explore whether qualitative and quantitative muscle ultrasound measures reflect the pattern of muscle involvement in IBM and are associated with magnetic resonance imaging (MRI) findings. Methods: Thirteen patients with histologically confirmed IBM underwent clinical evaluation, including the IBM Functional Rating Scale (IBM‐FRS) and Medical Research Council (MRC) grading. Qualitative (Heckmatt scale, from 1 to 4) and quantitative (muscle echo‐intensity and thickness z‐scores) ultrasound assessments were performed on fourteen muscles bilaterally. Lower limb muscle MRI was conducted using T1‐weighted (with Mercuri score) and STIR sequences. Correlations between ultrasound parameters and MRI findings were analyzed. Results: Qualitative ultrasound assessment showed increased echogenicity, mainly in flexor digitorum profundus, vastus lateralis, rectus femoris, tibialis anterior, and medial gastrocnemius. Quantitative analysis confirmed elevated echo‐intensity in these muscles, with milder involvement of tibialis anterior and lateral gastrocnemius. Both qualitative Heckmatt scores and quantitative muscle echo‐intensity scores showed positive associations with MRI T1 Mercuri scores ( p < 0.001). Discussion: In this study, both qualitative and quantitative muscle ultrasound reflected the characteristic pattern of muscle involvement in IBM and showed associations with MRI findings, supporting their utility in describing the pattern and extent of muscle damage.

  • Open Access

    Neurocognitive Therapeutic Exercise Integrated with Focal Mechanical Vibrations in a CANVAS Patient: A Case Report

    by Filippo Camerota, Filippo Mario Topa, Giuseppe Di Pietro, Federico Zangrando, Lorenzo Coluccia, Massimiliano Mangone, Marco Paoloni, Andrea Truini, Claudia Celletti

    Cerebellar Ataxia, Neuropathy and Bilateral Vestibular Areflexia Syndrome (CANVAS) is a progressive multisystem disorder characterized by cerebellar ataxia, sensory neuropathy and bilateral vestibular failure. Although intensive rehabilitation is commonly recommended, the actual effectiveness and the most appropriate physiotherapeutic strategy for CANVAS have not been clearly established. Background/Objectives: To evaluate the effects of an integrated rehabilitation program combining neurocognitive therapeutic exercise and focal muscle vibration (FMV) on clinical and instrumental measures of gait, balance and postural stability in a CANVAS patient. Methods: A structured protocol consisting of neurocognitive therapeutic exercise and FMV was administered. Clinical measures included the Berg Balance Scale, Tinetti, SARA and SF-36. The instrumental evaluations included stabilometry and gait analysis. Results: The intervention produced improvements in balance scores associated with a reduction in fall risk. Stabilometry revealed reduction in oscillation area. Conclusions: FMV combined with neurocognitive therapeutic exercise may promote clinical and biomechanical improvements in CANVAS.

  • Open Access

    A multicentre randomized double-blind placebo-controlled study of lacosamide, pregabalin, and tapentadol on spinal pain biomarkers

    by Caterina M. Leone, Giuseppe di Pietro, Giulia di Stefano, Charles Quesada, Charbel Salameh, Caroline Perchet, Luis Garcia-Larrea, André Mouraux, Louisien Lebrun, Solenn Gousset, et al.


  • Open Access

    Comparative Analysis of Small Nerve Fiber Density in Fibromyalgia Syndrome and Small Fiber Neuropathy

    by Pietro Falco, Eleonora Galosi, Caterina Maria Leone, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Nicoletta Esposito, Enrico Evangelisti, Daniel Litewczuk, Cristina Mollica, et al.

    Background/Objectives: Fibromyalgia syndrome is commonly associated with reduced intraepidermal nerve fiber density (IENFD), as assessed by skin biopsy, a finding referred to as small fiber pathology (SFP-FMG). The clinical significance of this abnormality, and how it relates to symptoms in fibromyalgia, remains uncertain. Reduced IENFD also represents the defining feature of small fiber neuropathy (SFN). While previous observations suggest that IENFD reduction is generally less severe in SFP-FMG than in SFN, no study has directly confirmed this finding in a large cohort. This retrospective study aimed to compare the severity of IENFD reduction in patients with SFP-FMG and those with SFN. Methods: To account for age and sex differences, we used the age-and sex-adjusted axonal loss density (ALD), defined as the percentage reduction from normative IENFD values. We retrospectively analyzed skin biopsy data from 73 patients with SFP-FMG and 134 patients diagnosed with SFN. Results: We found that the reduction in IENFD was significantly milder in patients with SFP-FMG than in those with SFN both at distal and proximal sites. Receiver operating characteristic analysis indicated that an ALD threshold of 37.6% provided good specificity for distinguishing SFN from SFP-FMG. Conclusions: These findings indicate that small fiber damage in fibromyalgia syndrome is quantitatively mild compared to patients with SFN. This may explain the absence of detectable sensory deficits on clinical examination and suggests a limited contribution of peripheral nerve damage to the pathophysiology of fibromyalgia syndrome.


  • Open Access

    Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects

    by Zahra Nochi, Hossein Pia, Petra Bloms-Funke, Irmgard Boesl, Ombretta Caspani, Sonya C. Chapman, Giuseppe Di Pietro, Francesca Fardo, Bernd Genser, Marcus Goetz, et al.

    Background: Chronic pain is a leading cause of disability globally, with limited treatment options and frequent adverse effects. The IMI-PainCare-BioPain project aimed to enhance analgesic drug development by standardizing biomarkers. This study, IMI2-PainCare-BioPain-RCT1, evaluated the effects of lacosamide, pregabalin, and tapentadol on peripheral nerve excitability in healthy subjects through a randomized, double-blind, placebo-controlled crossover trial. Methods: The study included 43 healthy participants aged 18 to 45 yr. Participants underwent four treatment periods during which they received single doses of lacosamide (200 mg), pregabalin (150 mg), tapentadol (100 mg), or placebo. High-frequency stimulation was applied to induce hyperalgesia. The two primary endpoints were changes in strength–duration time constant (SDTC) in large sensory and motor fibers between lacosamide and placebo periods at the first postdose timepoint compared to baseline (60 min). Other predefined endpoints included recovery cycle, threshold electrotonus (TEd), and S2 accommodation, as well as effects of pregabalin and tapentadol. Results: Lacosamide statistically significantly reduced SDTC in large sensory fibers (mean reduction, 0.04; 95% CI, 0.01 to 0.08; P = 0.012) and in motor fibers (mean reduction, 0.04; 95% CI, 0.00 to 0.07; P = 0.039) but had no effect on small sensory fibers at the first timepoint compared to placebo. There were no effects of pregabalin and tapentadol on SDTC. Of other predefined endpoints, lacosamide produced statistically significant changes in subexcitability, S2 accommodation TEd(peak), and TEd40(Accom) in large sensory fibers. No statistically significant changes were observed in refractoriness, relative refractory period, or accommodation half-time at the first timepoint compared to placebo. Conclusions: This study demonstrates that nerve excitability testing can detect pharmacodynamic effects on large myelinated fibers in healthy subjects. Lacosamide statistically significantly reduced peripheral nerve excitability, particularly in large sensory fibers.


  • Clinical, histologic, and immunologic signatures of Small Fiber Neuropathy in Systemic Lupus Erythematosus

    by Eleonora Galosi, Carmelo Pirone, Fulvia Ceccarelli, Nicoletta Esposito, Pietro Falco, Martina Leopizzi, Valeria Di Maio, Lorenzo Tramontana, Gianfranco De Stefano, Giuseppe Di Pietro, et al.

    Background and Objectives: Systemic Lupus Erythematosus (SLE) often causes damage to small nerve fibers, leading to distressing painful and autonomic symptoms. Despite this, Small Fiber Neuropathy (SFN) remains an underrecognized complication for SLE patients. In this cross‐sectional study, we aimed to assess SFN in patients with SLE and to explore its correlations with immunologic disease features and clinical manifestations.Methods: We recruited 50 SLE patients (1 male to 12.5 females, aged 20–80 years) reporting painful disturbances. We conducted a comprehensive clinical and neurophysiological evaluation, using Nerve Conduction Studies and Quantitative Sensory Testing. Additionally, we carried out an extensive laboratory assessment of disease‐related serological parameters. We also performed a thorough skin biopsy analysis, investigating somatic and autonomic innervation while detecting complement and inflammatory cell infiltrates within the skin.Results: Out of 50 patients, 19 were diagnosed with SFN, primarily characterized by a non‐length‐dependent distribution; 7 had a mixed neuropathy, with both large and small fiber involvement. Patients with SFN were younger than patients with a mixed neuropathy (p = .0143); furthermore, they were more likely to have a history of hypocomplementemia (p = .0058) and to be treated with cyclosporine A (p = .0053) compared to patients without neuropathy. However, there were no significant differences in painful and autonomic symptoms between patients with and without SFN.Discussion: This study highlights the relevant frequency of SFN with a non‐length‐dependent distribution among SLE patients experiencing painful symptoms. Indeed, SFN emerges as an early manifestation of SLE‐related neuropathy and is closely associated with hypocomplementemia, suggesting a potential pathogenic role of the complement system. Moreover, SFN may be influenced by disease‐modifying therapies. However, the precise role of SFN in shaping painful and autonomic symptoms in patients with SLE remains to be fully elucidated.